Skip to main content

Blepharitis

21
Pipeline Programs
10
Companies
13
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
9
0
2
10
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

10 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
7 programs
3
4
AzaSite®Phase 4
AzaSite®Phase 4
AzaSite®Phase 4
AzaSite®Phase 4
Azithromycin ophthalmic solution, 1%Phase 2
+2 more programs
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
7 programs
3
4
AzaSite®Phase 4
AzaSite®Phase 4
AzaSite®Phase 4
AzaSite®Phase 4
Azithromycin ophthalmic solution, 1%Phase 2
+2 more programs
Bausch + Lomb
Bausch + LombNJ - Bridgewater
1 program
1
ErythromycinPhase 4
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
ErythromycinPhase 41 trial
Active Trials
NCT01478256Completed30Est. Oct 2011
Alcon
AlconFORT WORTH, TX
2 programs
2
Moxifloxacin and Dexamethasone combinedPhase 31 trial
Tobradex STPhase 31 trial
Active Trials
NCT00732446Completed100Est. Feb 2009
NCT01102244Completed122
NicOx
NicOxFrance - Biot
2 programs
2
Fluticasone PropionatePhase 21 trial
NCX 4251Phase 21 trial
Active Trials
NCT03926026Completed36Est. Oct 2019
NCT04675242Completed224Est. Jun 2021
Galderma
GaldermaTX - Dallas
1 program
1
COL-101Phase 21 trial
Active Trials
NCT00560703Completed70Est. Jul 2009
Merck & Co.
Merck & Co.RAHWAY, NJ
3 programs
Azithromycin ophthalmic solution, 1%PHASE_23 trials
Azithromycin ophthalmic solution, 1%PHASE_21 trial
Azithromycin ophthalmic solution, 1%PHASE_21 trial
Active Trials
NCT01220258Terminated29Est. Aug 2011
NCT01105624Completed50Est. Nov 2010
NCT00892970Completed313Est. Jan 2010
+2 more trials
Optima
OptimaGermany - Schwaebisch Hall
1 program
Group AN/A1 trial
Active Trials
NCT01115192Completed144Est. Dec 2010
Thea Pharma
Thea PharmaMA - Waltham
1 program
AzithromycinPHASE_21 trial
Active Trials
NCT01089608CompletedEst. Jun 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bausch HealthErythromycin
Merck & Co.Azithromycin ophthalmic solution, 1%
AlconTobradex ST
AlconMoxifloxacin and Dexamethasone combined
NicOxNCX 4251
NicOxFluticasone Propionate
Merck & Co.Azithromycin ophthalmic solution, 1%
Merck & Co.Azithromycin ophthalmic solution, 1%
Thea PharmaAzithromycin
Merck & Co.Azithromycin ophthalmic solution, 1%
Merck & Co.Azithromycin ophthalmic solution, 1%
GaldermaCOL-101
OptimaGroup A

Clinical Trials (13)

Total enrollment: 1,472 patients across 13 trials

NCT01478256Bausch HealthErythromycin

Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis

Start: Aug 2011Est. completion: Oct 201130 patients
Phase 4Completed
NCT01105624Merck & Co.Azithromycin ophthalmic solution, 1%

A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)

Start: Mar 2010Est. completion: Nov 201050 patients
Phase 4Completed
NCT01102244AlconTobradex ST

A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis

Start: Apr 2010122 patients
Phase 3Completed
NCT00732446AlconMoxifloxacin and Dexamethasone combined

Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis

Start: Aug 2008Est. completion: Feb 2009100 patients
Phase 3Completed
NCT04675242NicOxNCX 4251

Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis

Start: Dec 2020Est. completion: Jun 2021224 patients
Phase 2Completed
NCT03926026NicOxFluticasone Propionate

Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis

Start: Mar 2019Est. completion: Oct 201936 patients
Phase 2Completed
NCT01269658Merck & Co.Azithromycin ophthalmic solution, 1%

A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis (P08636)

Start: Dec 2010Est. completion: Jun 201140 patients
Phase 2Terminated
NCT01220258Merck & Co.Azithromycin ophthalmic solution, 1%

A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)

Start: Nov 2010Est. completion: Aug 201129 patients
Phase 2Terminated
NCT01089608Thea PharmaAzithromycin

Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis

Start: Mar 2010Est. completion: Jun 2012
Phase 2Completed
NCT00894530Merck & Co.Azithromycin ophthalmic solution, 1%

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)

Start: May 2009Est. completion: Dec 2009314 patients
Phase 2Completed
NCT00892970Merck & Co.Azithromycin ophthalmic solution, 1%

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period

Start: Apr 2009Est. completion: Jan 2010313 patients
Phase 2Completed
NCT00560703GaldermaCOL-101

Treatment of Patients With Blepharitis and Facial Rosacea

Start: Nov 2007Est. completion: Jul 200970 patients
Phase 2Completed
NCT01115192OptimaGroup A

Blephacura Versus Baby Shampoo to Treat Blepharitis

Start: May 2010Est. completion: Dec 2010144 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.